33 results
Thumbnail

D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma

Thumbnail

D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)

Thumbnail

D1.152 - Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units

Thumbnail

D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites

Thumbnail

D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix

Thumbnail

D1.155 - Alterations in B cell memory induced by house dust mite allergen immunotherapy

Thumbnail

D1.156 - Early Immunologic Parameters Predicting Response to Sublingual Immunotherapy in Allergic Rhinitis Patients

Thumbnail

D1.157 - Type II Cytokine-Mediated Regulation of Alarmin Receptors in B Cells: Implications for Eosinophilic Esophagitis

Thumbnail

D1.159 - The successful resolve of nasal polyps in patient with dupilumab treatment

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Thumbnail

D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab

Thumbnail

D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age

Thumbnail

D2.362 - Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis

Thumbnail

D2.363 - Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience